Transient dominant selection of recombinant vaccinia viruses.
about
A new inhibitor of apoptosis from vaccinia virus and eukaryotesInsertion of the human sodium iodide symporter to facilitate deep tissue imaging does not alter oncolytic or replication capability of a novel vaccinia virusCloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cellsAnti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapyA conditional-lethal vaccinia virus mutant demonstrates that the I7L gene product is required for virion morphogenesisRecombinant Ranaviruses for Studying Evolution of Host-Pathogen Interactions in Ectothermic VertebratesUse of Reporter Genes in the Generation of Vaccinia Virus-Derived VectorsCoronavirus reverse genetic systems: infectious clones and repliconsImmunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletionsHighly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expressionInhibition of Apoptosis and NF-κB Activation by Vaccinia Protein N1 Occur via Distinct Binding Surfaces and Make Different Contributions to VirulenceDrug-Encoded Biomarkers for Monitoring Biological TherapiesVaccinia virus protein A49 is an unexpected member of the B-cell Lymphoma (Bcl)-2 protein familyRecombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapyA method for the generation of ectromelia virus (ECTV) recombinants: in vivo analysis of ECTV vCD30 deletion mutants.Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategiesCorrelates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates.Serp2, an inhibitor of the interleukin-1beta-converting enzyme, is critical in the pathobiology of myxoma virus.Horizontal transmissible protection against myxomatosis and rabbit hemorrhagic disease by using a recombinant myxoma virus.Clustered charge-to-alanine mutagenesis of the vaccinia virus H5 gene: isolation of a dominant, temperature-sensitive mutant with a profound defect in morphogenesisVaccinia virus F12L protein is required for actin tail formation, normal plaque size, and virulence.Role of vaccinia virus A20R protein in DNA replication: construction and characterization of temperature-sensitive mutants.The vaccinia virus superoxide dismutase-like protein (A45R) is a virion component that is nonessential for virus replication.Vaccinia virus intracellular movement is associated with microtubules and independent of actin tailsA selectable and excisable marker system for the rapid creation of recombinant poxviruses.Ectromelia virus inhibitor of complement enzymes protects intracellular mature virus and infected cells from mouse complement.Analysis of A47, an immunoprevalent protein of vaccinia virus, leads to a reevaluation of the total antiviral CD8+ T cell response.Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus AnkaraPoxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: pathogenesis, prophylaxis, and antiviral therapy.Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.Genetic screen of a library of chimeric poxviruses identifies an ankyrin repeat protein involved in resistance to the avian type I interferon response.Genetic screen of a mutant poxvirus library identifies an ankyrin repeat protein involved in blocking induction of avian type I interferon.Poxvirus targeting of E3 ligase β-TrCP by molecular mimicry: a mechanism to inhibit NF-κB activation and promote immune evasion and virulence.Mutations in modified virus Ankara protein 183 render it a non-functional counterpart of B14, an inhibitor of nuclear factor kappaB activation.N1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection.Mapping and functional analysis of interaction sites within the cytoplasmic domains of the vaccinia virus A33R and A36R envelope proteinsDeletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in miceTargeted construction of temperature-sensitive mutations in vaccinia virus by replacing clustered charged residues with alanine
P2860
Q21131614-ECE848F1-FF8D-418C-A947-475D6C797A8FQ21245462-2822A9D8-764A-4BA1-8348-936ADEE4BC3FQ24535851-1E9EADFD-4282-4E81-80AE-0530A9377F25Q24655930-07C3977B-9F5C-4E12-A30D-CB0F6CDAB400Q24804055-F3E085D1-F3E6-46C2-B136-A7CA9CA271E4Q26741288-26B83F92-9B6C-4884-930D-1D08C5C65F95Q26746915-3DEC6EEE-C198-48D2-AD01-DAAABB16DDABQ26863163-E8042F95-E227-44C1-A865-1AB0B4AFE0D4Q27320923-6766BB6A-8EAF-41D1-A69D-1303365AA2D7Q27469703-D5FFE18E-35D9-405B-AF4A-2C3B5F33DFD2Q27676390-E2808BB4-5778-4942-848E-43DEA7A20639Q28547768-F4446DEC-089B-4EB7-8A93-0D7D26EE32FDQ30370948-4FB28BA8-D460-42CB-9CFD-CC4E9AF5AEF8Q33320536-88935744-FF7D-45D6-ABE5-78812D3AC95BQ33399140-B41C7530-F92C-4F52-90C9-4ECDFAE24A3DQ33429965-945783F8-6A90-4467-ACE9-8A98375E785BQ33440600-69222A3F-2C28-4C0B-88D0-9A2190B42328Q33587040-8F403ADF-5BD8-4283-A268-430621C00545Q33784673-FAD8B3A5-3175-48EB-911E-E3BD5E120ED7Q33792968-E2ACDA7C-E916-4E39-8C14-A028E3F26C5FQ33799135-2DA47A54-1802-4CE7-A169-AC657706C8ACQ33812636-A2199A1B-4ECD-42AC-A070-44F2FAE0A840Q33837263-A92C9C2F-2427-4444-99BB-795CBCEF9D9CQ33844429-662B314F-CCBD-483D-9613-66EB1FBD3C5FQ33849999-6BE6C004-36D7-464B-826E-6A6E822DDF7AQ34023827-351E5B51-AEA0-4C29-944A-1F1A0E665E4AQ34120177-153E75E2-177F-4040-925A-E66FB97C4687Q34120775-50BA0791-4AF7-4B5C-9EAB-330D16BB19AEQ34343169-FE4B256B-B33D-4C5D-A569-3B827C433ACFQ34432037-B224974C-5A9E-40A5-9F21-3A29B3F504B9Q34455259-68601E80-906D-41E1-8563-06329E65108CQ34593862-FF56FDF5-FE63-418E-B049-976686EBC7DEQ34593871-1162FFED-2879-423D-A4B8-30E95787370DQ34611139-473F6FC9-4A62-409B-B01C-29297814F5ECQ34641590-AEF6936B-7431-409A-805D-8C0826D8CAACQ34742613-92666E70-C2A1-4607-97CE-036E6D91DE54Q34781856-3EA6F2DA-C8E5-4DD5-BD8A-54EA38BB7DA6Q35076706-9C3AE24B-21F8-4027-A238-5D8C969D8651Q35202797-24E8DD24-5041-4805-86DC-5CC99FAD69A1Q35243398-FEE008F4-3B08-41D4-9469-C752FCA05C17
P2860
Transient dominant selection of recombinant vaccinia viruses.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
Transient dominant selection of recombinant vaccinia viruses.
@ast
Transient dominant selection of recombinant vaccinia viruses.
@en
type
label
Transient dominant selection of recombinant vaccinia viruses.
@ast
Transient dominant selection of recombinant vaccinia viruses.
@en
prefLabel
Transient dominant selection of recombinant vaccinia viruses.
@ast
Transient dominant selection of recombinant vaccinia viruses.
@en
P2860
P1433
P1476
Transient dominant selection of recombinant vaccinia viruses
@en
P2093
P2860
P304
P407
P577
1990-06-01T00:00:00Z